CHMP backs J&J’s myeloma bispecific Tecvayli, ahead of US decision
pharmaphorum
JULY 25, 2022
Tecvayli previously scored a priority medicines (PRiME) designation from the EMA and a breakthrough-therapy tag from the FDA. Pfizer is hot on J&J’s heels with its BCMA and CD3 bispecific antibody elranatamab, and reported phase 2 data at ASCO this year in a similarly heavily pre-treated patient population.
52 
Let's personalize your content